コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 inflammation while preserving and enhancing protective immunity.
2 antigen misfolding, hindering generation of protective immunity.
3 tion following vaccination in the absence of protective immunity.
4 been impeded by the absence of correlates of protective immunity.
5 ed by poor understanding of what constitutes protective immunity.
6 , indicating the generation of CT26-specific protective immunity.
7 (+) memory T lymphocytes that participate in protective immunity.
8 n targeting blood-stage parasites results in protective immunity.
9 ant glycoprotein in serum and is crucial for protective immunity.
10 generating IFN-alpha/beta-induced subsequent protective immunity.
11 ) vaccine modalities as a strategy to induce protective immunity.
12 ts that primary Zika virus infection elicits protective immunity.
13 phagocytosis (ADCP) activity, implicated in protective immunity.
14 eptors to detect microorganisms and activate protective immunity.
15 zation strategies are needed to induce cross-protective immunity.
16 nteractions among innate cells that initiate protective immunity.
17 ell response is believed to be important for protective immunity.
18 cating that the vaccines elicited long-lived protective immunity.
19 ed, yet it replicates sufficiently to elicit protective immunity.
20 ar kinetics and induced comparable levels of protective immunity.
21 arameters are often inadequate predictors of protective immunity.
22 atory mechanisms that limit the induction of protective immunity.
23 ecognition receptors (PRRs) is essential for protective immunity.
24 et of these antigens are necessary to elicit protective immunity.
25 e of antigens as a key effector for inducing protective immunity.
26 JENVAC elicits long-lasting, broadly protective immunity.
27 n a single vaccine organism for induction of protective immunity.
28 were not attacked a second time, suggesting protective immunity.
29 an effective NoV vaccine must elicit broadly protective immunity.
30 gnitude, antibodies may act as biomarkers of protective immunity.
31 for potent invasion-inhibitory activity and protective immunity.
32 mulating T cells may provide important cross-protective immunity.
33 n of rhoptries, is also critical in mounting protective immunity.
34 eting distinct epitopes may be necessary for protective immunity.
35 g damaging immunopathology and by inhibiting protective immunity.
36 ed MAIT cells are important for tuberculosis protective immunity.
37 inform ZIKV vaccine strategies for inducing protective immunity.
38 search for malaria antigens associated with protective immunity.
39 the way for better vaccine design to achieve protective immunity.
40 T lymphocytes (CTLs) in heterosubtypic cross-protective immunity.
41 CD8(+) T cells capable of mediating durable protective immunity.
42 in peripheral tissues have distinct roles in protective immunity.
43 ical for systemic, but not mucosal, T. cruzi protective immunity.
44 this subset to improve the effectiveness of protective immunity.
45 CD8(+) T cells are an essential component of protective immunity.
46 idly protected macaques completely abrogated protective immunity.
47 mately 7 days before they are able to elicit protective immunity.
48 tabolism to persist in tissue and to mediate protective immunity.
49 esponse associated with parasite killing and protective immunity.
50 mpartment may provide organisms with broader protective immunity.
51 and that antineuraminidase antibodies offer protective immunity.
52 ic cellular and humoral responses, including protective immunity.
53 in live-attenuated trachoma vaccine-mediated protective immunity.
54 ccine is the identification of mechanisms of protective immunity.
55 l for DC maturation, which may contribute to protective immunity.
56 ith negligible off-target effects, to induce protective immunity.
57 innate immunity and its poor elicitation of protective immunity.
58 ent of IL-17-dependent, Th cell-transferable protective immunity.
59 tural killer (NK) cells were dispensable for protective immunity.
60 nological memory to vaccines is critical for protective immunity.
61 ow recognized as a syndrome of aberrant host protective immunity.
62 PfCSP-reactive B cells in PfSPZ-CVac-induced protective immunity.
63 leads to T cell dysfunction and compromised protective immunity.
64 or models, including complete responses with protective immunity.
65 may contain important epitopes for inducing protective immunity.
66 of VM cells, including their likely role in protective immunity.
67 but they require about 5 to 7 days to induce protective immunity.
68 nce to virus or viral components, can induce protective immunity.
69 -transfer experiments also revealed that the protective immunity afforded by vaccination with the bat
71 xplore the role of TRM cells in local tissue protective immunity after rechallenge and vaccination.
72 t lead to the initiation of CD8 TRM-mediated protective immunity after viral infection are unclear.
74 is system is the first capable of generating protective immunity against a broad spectrum of lethal p
75 erior humoral immune responses and conferred protective immunity against a lethal challenge dose of h
76 verely attenuated in vivo but able to elicit protective immunity against a lethal challenge with wild
77 verely attenuated in vivo but able to elicit protective immunity against a lethal challenge with wild
78 observable toxicity in animals and achieved protective immunity against a lethal influenza challenge
79 nstrate that CD8(+) T cells are required for protective immunity against a naturally occurring murine
80 we evaluated whether alpha-GalCer generates protective immunity against a swine influenza (SI) virus
81 to macaques elicited either solid or partial protective immunity against a virulent ocular challenge.
82 coding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolaviru
84 orm to gain insights regarding mechanisms of protective immunity against B. mallei and B. pseudomalle
85 gamma receptor I (FcgammaRI) contributes to protective immunity against bacterial infections, but ex
88 IEC-produced IL-7 was only essential for protective immunity against C. rodentium during the firs
90 es have proven attenuated in swine, inducing protective immunity against challenge with homologous pa
91 and the tex mutant was capable of providing protective immunity against challenge with wild-type B.
93 important implications for the induction of protective immunity against Chlamydia and other infectio
96 challenges to defining immune correlates of protective immunity against DENV in field efficacy studi
97 Persistent parasites play a vital role in protective immunity against disease pathology upon reinf
99 the primary antigenic components involved in protective immunity against encapsulated bacterial patho
101 y cholesterol-modified p40-siRNA established protective immunity against experimental autoimmune ence
102 Immune homeostasis is a prerequisite to protective immunity against gastrointestinal infections.
103 his study demonstrates that the cross-mucosa protective immunity against genital C. trachomatis infec
104 demonstrate that IL-25 is critical for host protective immunity against H. polygyrus bakeri infectio
106 unization with PR8-amiR-93NP conferred cross-protective immunity against heterologous influenza virus
107 promising candidates to examine induction of protective immunity against heterologous pathogens.
114 Memory cells are a critical component of protective immunity against invading pathogens, especial
117 evelopment of vaccine-induced Th17 cells and protective immunity against lethal experimental infectio
119 Current understanding of the mechanisms of protective immunity against lung infection has been larg
122 ce that exceed the threshold correlated with protective immunity against multiple strains of Zika vir
126 es, induced a strong CD8(+) T cell-dependent protective immunity against ocular herpes infection and
127 TEM cells that were associated with a strong protective immunity against ocular herpes infection and
128 ific CD8(+) TEM cells associated with strong protective immunity against ocular herpesvirus infection
129 ecific CD8(+) T cells associated with strong protective immunity against ocular herpesvirus infection
131 CD4 TEMRA cells have been implicated in protective immunity against pathogens such as dengue vir
133 nfection of ERBs with MARV induces long-term protective immunity against reinfection and indicates th
136 contribution of Th2 cells and basophils for protective immunity against S. mansoni egg-induced patho
137 e efficacy of these NP adjuvants in inducing protective immunity against simian immunodeficiency viru
138 cination with the batA mutant strain elicits protective immunity against subsequent infection with wi
141 m infection and plays a critical role in the protective immunity against this intestinal attaching an
143 While first infection confers long-term protective immunity against viruses of the infecting ser
144 a SseB with flagellin substantially enhances protective immunity, allowing immunized C57BL/6 mice to
147 dentify antigenic regions that contribute to protective immunity and are therefore the key targets of
148 mechanism has likely evolved to both sustain protective immunity and avoid autoantibody production.
149 ng the impact of OAS phenotype antibodies on protective immunity and disease severity in secondary in
151 receptors that regulate the balance between protective immunity and host immune-mediated damage.
152 rus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab ther
156 e T-cell homeostasis is essential to promote protective immunity and limit autoimmunity and neoplasia
158 as for anthrax, for which rapid induction of protective immunity and memory with a single injection i
161 ogenes infection inhibited the generation of protective immunity and specifically the activation of a
162 ne aging results in progressive loss of both protective immunity and T cell-mediated suppression, the
163 -modified mRNA-LNP elicits rapid and durable protective immunity and therefore represents a new and p
165 sentation, can be targeted in vivo to induce protective immunity, and share characteristics with XCR1
166 he emerging evidence of their importance for protective immunity, and the potential role of resident
167 ogens, we validate that the prime targets of protective immunity are conformational epitopes at the d
171 ll responses.IgE is an important mediator of protective immunity as well as allergic reaction, but ho
172 ed antibody response plays critical roles in protective immunity, as well as in the pathogenesis of a
173 ays, which may not provide a true measure of protective immunity associated with H7 immunization.
176 s a pathway for the restoration of long-term protective immunity based on metabolically modified cyto
177 s early sensors of danger signals, mediating protective immunity both through licensing of cellular e
178 Fc receptors on basophils were required for protective immunity but not for regulation of basophil h
179 ously drift, which allows them to circumvent protective immunity, but conserved epitopes provide immu
180 te pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an
181 ody response to HPVs is a key determinant of protective immunity, but not all infected individuals se
182 ovirus is an avirulent pathogen that elicits protective immunity, but we discovered that it can nonet
183 focus of vaccine research aimed at inducing protective immunity by antibodies as well as efforts to
185 s vaccine research toward a goal of inducing protective immunity by using WT GP antigens in candidate
186 re, we have pursued a strategy for eliciting protective immunity by vaccinating with small molecules
187 n of pathways related to neutrophil-mediated protective immunity, chemokine/chemokine receptor bindin
189 tivity, as well as its multifaceted roles in protective immunity, control of mast cell homeostasis, a
190 ice with a C. neoformans strain that induces protective immunity demonstrated that recruitment of pDC
191 ts in our understanding of the mechanisms of protective immunity, demonstrating a need to measure epi
192 ylococcus aureus infections fail to generate protective immunity despite detectable T and B cell resp
194 ion by Toxoplasma gondii triggers a lifelong protective immunity due to the persistence of parasitic
195 g antigen presentation and the generation of protective immunity during vaccination or infection.
196 er side of the outer membrane indicates that protective immunity elicited by this antigen cannot be d
197 likely to be associated with differences in protective immunity, especially cross-protection against
199 s against which IgE is an observed marker of protective immunity explains the 'off-target' effects of
200 ctions as a negative regulator to limit host-protective immunity following intradermal infection with
201 hown to induce complete tumor regression and protective immunity following intralesional treatment of
202 epidemiologic settings and demonstration of protective immunity for GII infections provide support f
203 hylococcus aureus does not induce long-lived protective immunity for reasons that are not completely
205 f Plasmodium vivax reticulocyte invasion and protective immunity have hampered development of vivax v
206 studies typically examined the biomarkers of protective immunity however the biomarkers of attenuatio
207 lose important epitopes for inducing robust protective immunity.IMPORTANCE The emerging, highly viru
208 dermal model of infection yet still elicited protective immunity.IMPORTANCE The vaccinia virus (VACV)
211 ported to be associated with vaccine-induced protective immunity in challenge studies involving nonhu
220 trains have affected regions responsible for protective immunity in order to decide when new vaccine
221 tosolic multiprotein complexes that initiate protective immunity in response to infection, and can al
223 replication in vivo, may lead to the lack of protective immunity in swine observed after challenge.
224 oreover, by lowering opportunities for cross-protective immunity in the population, conventional vacc
229 th mucosal surfaces where they contribute to protective immunity, inappropriate allergic responses, a
231 mulation of CD8(+) T cells in the liver, and protective immunity induced by immunization with the Pla
233 ng the high-avidity epitope SSIEFARL induced protective immunity irrespective of gene expression cont
234 with multiple exacerbations, development of protective immunity is critical to improving patient sur
236 tigation of tractable model systems in which protective immunity is effective has provided a mechanis
240 We uncover two inter-organ mechanisms of protective immunity mediated by soluble and cellular fac
242 osal delivery would ensure the best onset of protective immunity, most of the candidate vaccines are
244 juvant properties that improve SseB-mediated protective immunity provided by circulating memory.
246 against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV fiel
250 uss the central role of the GI microbiota in protective immunity, resistance to enteric pathogens, an
251 al infection leads to partial but incomplete protective immunity, resulting in subsequent reinfection
252 ass I on CD301b(+) dendritic cells abrogates protective immunity, suggesting the requirement for cogn
253 Chlamydia trachomatis (Ct) infection induces protective immunity that depends on interferon-gamma-pro
254 nd interferon upregulation all contribute to protective immunity that occurs in humans following infl
255 tion in a critical temporal window to impede protective immunity through cytotoxic-T-lymphocyte-assoc
256 1 and Th17 cells have an established role in protective immunity to Bordetella pertussis, but this ev
259 dentity of the specific microbes that elicit protective immunity to different infections is less clea
260 sponses are necessary for the development of protective immunity to helminth parasites but also cause
261 tentially novel correlates and mechanisms of protective immunity to HIV vaccination, thus offering a
264 ccines have proved ineffective at conferring protective immunity to infants and the elderly, age coho
267 identify key immune epitopes responsible for protective immunity to influenza virus in humans and the
271 rasitic infection, and indicate that optimal protective immunity to Leishmania, and thus the success
272 uenza A virus (IAV) and were responsible for protective immunity to lethal challenge with pathogenic
273 her delineate mechanisms whereby HIV impairs protective immunity to M. tuberculosis, we evaluated the
276 systems, it is unclear which are involved in protective immunity to natural infection in humans.
278 designing strategies for the development of protective immunity to pathogens that induce immune resp
281 la virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EB
283 mimics human infection, we show that lack of protective immunity to S. aureus systemic reinfection is
285 rcome a defect of CD4(+) T cells in inducing protective immunity to vaccination with a T-dependent in
286 ional profiles suggest a capacity to mediate protective immunity via antigen non-specific bystander k
287 antibody-dependent mechanisms contribute to protective immunity via distinct targets whose identific
290 mutant was tested for its vaccine potential, protective immunity was generated in a vaccine/challenge
291 ry environment that favors the generation of protective immunity, whereas tumors are characterized by
292 gen on MHC-I was essential for bTRM-mediated protective immunity, which involved perforin- and IFN-ga
293 ysts in the host or the presence of lifelong protective immunity, which led us to question this dogma
294 sal immune system must initiate and regulate protective immunity, while balancing this immunity with
295 trial, which demonstrated a rapid waning of protective immunity with time, have underscored the need
296 l tumor-associated stroma (TAS) to configure protective immunity within the tumor microenvironment.
297 pproach both mice and swine exhibited strong protective immunity without incurring any appreciable sk
299 velop vaccines against RSV that will provide protective immunity without the potential for disease en
300 tory syncytial virus (RSV) that will provide protective immunity without the potential for vaccine-as
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。